2022
DOI: 10.1038/s41576-021-00439-4
|View full text |Cite
|
Sign up to set email alerts
|

Drug delivery systems for RNA therapeutics

Abstract: RNA-based gene therapy requires therapeutic RNA to function inside target cells without eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug delivery systems, which circumvent the limitations of viral delivery vectors. Here, we review the growing number of RNA therapeutic classes, their molecular mechanisms of action, and the design considerations for their respective delivery platforms. We describe polymer-based, lipid-based, and conjugate-based drug delivery systems, differ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
406
0
4

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 590 publications
(508 citation statements)
references
References 249 publications
0
406
0
4
Order By: Relevance
“…The last five years have witnessed the approval of several oligonucleotides for human use [1,2]. A major success in this field is the development of the active targeting system based in the use of the triantennary GalNAc ligand directly conjugated to the nucleic acid part [32]. This ligand directs the therapeutic oligonucleotides to hepatocytes [12].…”
Section: Discussionmentioning
confidence: 99%
“…The last five years have witnessed the approval of several oligonucleotides for human use [1,2]. A major success in this field is the development of the active targeting system based in the use of the triantennary GalNAc ligand directly conjugated to the nucleic acid part [32]. This ligand directs the therapeutic oligonucleotides to hepatocytes [12].…”
Section: Discussionmentioning
confidence: 99%
“…Another challenge for tissue delivery is oligonucleotide stability in circulation ( Paunovska et al, 2022 ). Much of this issue has been solved, either by encapsulation of the oligonucleotide in an LNP, or by installment of RNA modifications ( Yu et al, 2019 ).…”
Section: Function Of Trfs and Tirsmentioning
confidence: 99%
“…Therefore, the intrinsic cytotoxicity of unmodified PEI originating from the strong cationic charge density and degree of branching represents a serious concern in biomaterial application and clinical use [16,44,51]. In this respect, numerous approaches have been deployed, showing that chemically modified PEI derivatives may overcome some of these shortcomings, being capable of improving in vivo efficacy and tolerability as well as transfection efficiency and targeting ability to specific cells or populations [13,53]. For instance, polyethylene glycol (PEG)-grafted PEI formulation condensing mRNA shows remarkable transgene expression levels in pulmonary immune cells following systemic administration [54], and chemically modified PEI with chondrocyteaffinity peptides [55] or cyclodextrin-PEI conjugates [56] have been demonstrated to be potent and feasible gene carriers in vivo.…”
Section: Opportunitiesmentioning
confidence: 99%